StemCell Therapy

Innovative Report on BiopreservationMarket with Competitive Analysis, New Business Developments, and Top Companies

A perfect mix of quantitative & qualitativeBiopreservationMarketMarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Biopreservation Market. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

Prominent players profiled in the study:, Thermo Fisher Scientific, GE Healthcare, Sigma-Aldrich(Merck), VWR International, Lonza, Biolife Solutions, STEMCELL Technologies, WAK-Chemie Medical GmbH

Sample Report with Latest Industry Trends @https://grandviewreport.com/sample/20475

This Report Provides an overview of the Biopreservationmarket, containing global revenue,global production, sales, and CAGR.Also describe Biopreservationproduct scope, market overview, market opportunities, market driving force, and market risks. The forecast and analysis of the Biopreservationmarket by type, application, and region are also presented. The next part of the report provides a full-scale analysis of Biopreservationcompetitive situation, sales, revenue and global market share of major players in the Biopreservationindustry. The basic information, as well as the profiles, applications, and specifications of products market performance along with Business Overview, are offered.

The key product type of Biopreservationmarket are:, Home-Brew Media, Pre-Formulated Media

BiopreservationMarket Outlook by Applications:, Drug Discovery, Regenerative Medicine, Biobanking

Geographical Regions:North America, Europe, Central & South America, Asia-Pacific, and the Middle East & Africa, etc.

Get Reasonable Discount on this Premium Report @https://grandviewreport.com/discount/20475

Scope of the BiopreservationReport:

This report covers the current scenario and growth prospects of the BiopreservationMarket for the period 2020-2025. The study is a professional and in-depth study with around tables and figures which provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the domain.

Finally, all aspects of the Global BiopreservationMarket are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and future prospects.

Browse Full[emailprotected]https://grandviewreport.com/industry-growth/Biopreservation-Market-20475

Read the original:
Biopreservation Market share forecast to witness considerable growth from 2020 to 2025 | By Top Leading Vendors , STEMCELL Technologies, WAK-Chemie...

ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

Original post:
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference - Yahoo Finance

The global Cancer Stem Cells marketis forecast to reach USD 2.18 Billion by 2027, according to a new report by Reports and Data. The market for stem cells for cancer is experiencing increased growth due to the rising number of clinical trials globally. Stem cells are used in regenerative medicine, particularly in the field of dermatology. However, its applications in oncology will witness higher growth rate due to a large number of ongoing pipeline projects for the treatment of cancer or tumors.

The report sheds light on the emerging trends and changes in the market dynamics with regards to the current COVID-19 pandemic. The economic landscape and the market environment have observed drastic changes due to the social restrictions and government-enforced lockdowns imposed to curb the spread of COVID-19. The report is furnished with the latest scenario and growth outlook of the market with regard to the impact of the pandemic. The report covers an extensive impact analysis of the COVID-19 impact on the overall industry and provides a post-COVID-19 perspective of market growth and trends.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3047

The report comprises statistical data neatly organized in the form of graphs, charts, figures, diagrams, and tables to offer a better understanding of the workings of the Cancer Stem Cells industry. The report additionally provides a detailed profiling of the leading market players as well as a regional analysis to understand the landscape and growth curve of the Cancer Stem Cells industry.

The report further provides an extensive report of the key companies and their market share and size in each region. It further talks about the sales network and distribution channels, production, and consumption patterns in each region, and the expected revenue generation and contribution from each segment of the market in each key region.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

AbbVie, Inc., Bionomics, Thermo Fisher Scientific, Inc., Merck KGaA, LONZA, Miltenyi Biotec, Stemline Therapeutics, Inc., PromoCell GmbH, Irvine Scientific, and MacroGenics, Inc., among others.

The Cancer Stem Cells market report provides an estimation of the value of market and market volume. The report further examines and estimates segments and sub-markets in the overall Cancer Stem Cells industry. The report provides an 8-year forecast estimation from 2020 to 2027 inclusive of a range of indices such as supply and demand ratio, production and consumption ratio, market growth, technological innovations, key players of the industry, and product portfolio. It further discusses in detail the revenue estimations, gross margin, sales patterns, and manufacturing cost analysis that will provide a better idea about the global Cancer Stem Cells industry.

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/3047

For the purpose of this report, Reports and Data have segmented the global Cancer Stem Cells market on the basis of treatment type, end-user, disease type, and region:

Treatment Type Outlook (Revenue, USD Billion; 2017-2027)

Disease Type Outlook (Revenue, USD Billion; 2017-2027)

End-User Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3047

Geographical Analysis of the Cancer Stem Cells Industry:

On the basis of the spread of the Cancer Stem Cells industry in the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The report is analyses the key regions for the production, consumption, revenue, market share, market size, and growth rate of the Cancer Stem Cells industry in these regions for the forecast timeline 2020-2027. The report also provides a country-wise analysis of the Cancer Stem Cells market wherein major countries from the key geographical regions such as the United States, Mexico, Brazil, India, Japan, China, Australia, the U.K, Germany, Saudi Arabia, U.A.E., and other major countries.

In conclusion, the report gives a comprehensive overview of the revenue estimation, market trends, growth factors, and the regional bifurcation of the Cancer Stem Cells industry. It additionally presents SWOT analysis, Porters Five Forces Analysis, Feasibility analysis, and investment return analysis. The report also provides strategic recommendations to the established companies as well as new entrants to assist them in making fruitful business and investment decisions.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/cancer-stem-cells-market

Thank you for reading our report. For further inquiry about customization, kindly get in touch with us and our team will make sure the report is best suited for your needs.

Read more:
Cancer Stem Cells Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2027 | AbbVie, Inc., Bionomics, Thermo...

Global Bio-Banks Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ 6.7 Bn by 2026, at CAGR of XX% during forecast period.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30199

Advancement in biobanking operations in order to ensure optimization of sample storage and maintenance is one of the key factors driving this market. Regenerative medicine through stem cell technology is one of the important treatments for diseases, like Alzheimers, diabetes, cancers, and rare genetic diseases. In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved. With the increase in awareness about stem cell therapies, there has been a larger number of parents who are choosing umbilical cord banks for their children. There are a number of donor banks that are coming up as well. Biobanks not only support in the therapies for genetic diseases but also in medical research on rare genetic disorders. Growing awareness about stem cell therapies and innovation in the field of regenerative medicine are driving the growth of the global biobank market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Growing in the incidence of chronic diseases, government initiatives, development in drug discovery, and innovation of regenerative medicines, increasing healthcare expenditure and improvement in the treatment of cell and tissue disorders are some of the key factors boosting the global biobanks market. Furthermore, increasing awareness about biobanks is projected to boost the market for biobanks. Rising demographics, economies, and growth in GDP in the emerging countries like India and China, technological advancement and new innovate techniques are expected to offer good opportunities in the global biobanks market. Green banking and virtual biobanks for energy efficiency are some of the key trends that have been observed in global biobanks market. At the same time, expensive techniques, lack of standardization, economic recession and ethical issues related are some of the major factors limiting the growth for global biobanks market.

According to various application, the biobank application is expected to hold a XX% share during the forecast period. On account of different biospecimens stored at biobanks are witnessing significant demand because to advancements in cell-based research activities. Growing demand from different end users has led to the establishment of a substantial number of population-based and disease-based banks in a few years. Population-based banks are established to support precision medicine research initiatives, whereas disease-specific biobanks provide resources to research communities to enable a better understanding of disease etiology.

Among the regions, North America presently leads the global market for biobanks, closely followed by Europe, and it is expected to expand further at the highest CAGR during the forecast period. The increasing demand for Bio-Banks in the U.S. and Canada has allowed the province to have the highest market share. The prominence of these regions on account of the increasing incidence of chronic diseases, the imperative need to find effective treatments for them, large amounts of government investments in the area of biobanks, and the growing number of research activities, together with drug discovery in the region.

The Bio-Banks market report contains in-depth analysis of major drivers, opportunities, challenges, industry trends and their impact on the market. The Bio-Banks market report also provides data about the company and its strategy. This report also provides information on the competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. This research report also adds a snapshot of key competition, market trends during the forecast period, expected growth rates and the primary factors driving and impacting growth market data. This information will be beneficial or helpful to the decision makers.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global Bio-Banks market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global Bio-Banks market.Scope of Global Bio-Banks Market:

Global Bio-Banks Market, ByType:

Optimized Pre-Formulated Media Non-Optimized, Isotonic Formulation MediaGlobal Bio-Banks Market, By Product:

Refrigerators Ice Machines Freezers LN2 Supply Tanks Alarm and Monitoring Systems Cryogenic Storage Systems AccessoriesGlobal Bio-Banks Market, By Application:

Biobanking Regenerative Medicine Drug DiscoveryGlobal Bio-Banks Market, By Analysis:

Human tissue and tumor cells Bio-fluids Stem cells Umbilical cordGlobal Bio-Banks Market, By Region:

North America Europe Asia-Pacific South America Middle East & AfricaKey Players Operated in Market Include:

Home-Brew media solutions Teva Pharmaceuticals Organ Recovery Systems Genzyme Thermofisher Scientific VWR International Beckman Coulter Inc. Taylor-Wharton Tecan AG Panasonic Biomedical Sales Europe B.V. Thermo Fisher Scientific Inc. Taylor-Wharton International LLC So-Low Environmental Equipment Co. BioCision VWR International, LLC Beckman Coulter, Inc. BioLife Solutions, Inc.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30199

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/30199

MAJOR TOC OF THE REPORT

Chapter One: Bio-Banks Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Bio-Banks Market Competition, by Players

Chapter Four: Global Bio-Banks Market Size by Regions

Chapter Five: North America Bio-Banks Revenue by Countries

Chapter Six: Europe Bio-Banks Revenue by Countries

Chapter Seven: Asia-Pacific Bio-Banks Revenue by Countries

Chapter Eight: South America Bio-Banks Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Bio-Banks by Countries

Chapter Ten: Global Bio-Banks Market Segment by Type

Chapter Eleven: Global Bio-Banks Market Segment by Application

Chapter Twelve: Global Bio-Banks Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Bio-Banks Market Report at:https://www.maximizemarketresearch.com/market-report/global-bio-banks-market/30199/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

More:
Global Bio-Banks Market : Industry Analysis and Forecast (2019-2026) By Type, Product,Application,Analysis,and Region. - Galus Australis

Theres a lot to like about growth stocks. They can provide a healthy shot in the arm to an otherwise flat portfolio. Which makes sense. When a company is growing faster than the market average, the stock price usually isnt far behind. But to really reap the benefits, high-growth stocks offer the most potential bang for the buck.

So whats the difference between a regular growth stock and a high-growth stock? The answer is maturity.

Now, there are a lot of ways to pinpoint a growth stock. The classic metric is finding one with a high price-to-earnings (P/E) ratio. But most high-growth stocks are still flying under the radar of the average investor. Thats because theyve got a lot of growing left to do.

Finding a stock that has yet to hit its growth spurt can be like looking for a needle in a haystack. Theyre not quite the talk of Wall Street yet. But theyve got all of the characteristics in place to dominate their respective industry.

Lets start with a classic. Amazon (Nasdaq: AMZN) has been considered a growth stock for most of its existence. The e-commerce giant started off by going years without turning a profit. Instead of taking the opportunity to excite investors with booming profits, CEO Jeff Bezos reinvested nearly every dime the company made back into itself.

It proved to be a fruitful move. These days, Amazon controls nearly50% of all e-commerce. And it got there by focusing on growth. In the meantime, investors that stuck with the company through its heady adolescence have been handsomely rewarded.

Amazons P/Estayed above 70 from 2019 to 2020. So investors still believe it will have high earnings growth. But beyond world domination, it cant possibly maintain the growth trajectory its already undergone.

Despite the fact that Amazon is an extremely large blue chip stock, its EPS growth expectations over the next five years sit around 30%. So its still a solid investment If you can afford to get in. Heck, even if you cant afford a full share, theres a solid case to be made for investing in Amazon.

But for our purposes, were looking for a stock thats not just in a position to outpace the greater markets But one thats positioned to blow the doors off the market average.

And one thats in a perfect position to do so is Digital Turbine (Nasdaq: APPS).

As the companys ticker suggests, this potential high-growth stock is in the mobile app business. But its positioned in a rather unique way. Digital Turbine acts as a third party that works with wireless carriers to preinstall apps on new cell phones. It then sells available slots to companies like Uber, Spotify and Amazon that want their apps on phones. And business is going well.

Digital Turbine has also developed a strategic partnership with Samsung, the largest cellphone manufacturer in the world. This arms the company with a potent ally in the world of mobile advertising. Digital Turbine also boasts an impressive 92 P/E ratio that could signal significant future growth At least until the whole cell phone fad dies out. But until that happens, Digital Turbine could be just the propellant a sluggish portfolio needs.

The second potential high-growth stock is BioLife Solutions (Nasdaq: BLFS). This companys been around for a little longer than Digital Turbine. But that just means its had more time to perfect what it does.

BioLife is a leader in the medical instrument and supply industry Thanks in no small part to some state-of-the-art developments its spearheaded.

Sorry in advance for the 10-dollar words, but BioLife develops, manufactures and supplies:

While this might not sound all that important to the average investor, these two developments are huge. This biobanking technology is used in regenerative medicine Its essential for medical research And it plays an essential, supporting role in drug and therapy development.

In other words, when theres a medical breakthrough, theres a decent chance that BioLife played a role. And in an age when nobody knows when the next disease will pop up, BioLife Solutions has positioned itself to play a vital role treating it.

BioLife also boasts strong, innovative leadership in its CEO, Michael Rice, and a high P/E ratio over 170 Making this an enticing high-growth stock.

Cybersecurity is big business. But its a pretty crowded field. Which is why a company like FireEye (Nasdaq: FEYE) can easily get looked over by investors. There are, however, plenty of reasons to give this potential high-growth stock a second look.

Year-over-year sales growth of just 6% seemingly hit a bit of a snag this year. But whats not accounted for was the companys massive (and expensive) shift to cloud-based services.

By jumping into the subscription-based model, FireEye has set itself up with a strong baseline of future revenue And it still has plenty of time to put the pedal to the metal as cybersecurity demands increase.

With a broad array of cybersecurity products for healthcare, government, financial services and personal cloud computing, FireEyes seasoned leadership is proving to be guiding the company in all of the right directions.

A company on the rise can make a huge difference in any investors portfolio. But like all investments, they come with some inherent risk. And because most high-growth stocks dont offer dividends (but there are exceptions like these dividend growth stocks) the only way to make money off them is by selling them in the future.

But thats not the only risk. When it comes to young companies, missing expectations can cause a lot more tumult both for the business and stock price than it would for a blue chip stock. So before you take the plunge on any investment, its important to first come to grips with your risk tolerance.

If you decide that high-growth stocks are right for you, we wish you good investing. If however, you dont have the stomach for it, there are plenty of other investment opportunities out there.

And if youd like to have up-to-the-minute market analysis delivered to your inbox every day, be sure to sign up for the Investment U e-letter below.

Go here to see the original:
3 High-Growth Stocks to Watch in 2020 - Investment U

Global 3D Printed Implants Market: An Overview

The global 3D printed implants market is an important part of the growing larger trend, the 3D printing in medical applications.

The global 3D printed implants market players are serving a crucial need of the medical sector. Medical processes can be enhanced with training on artificial models before surgeries. Additionally, the products in the global 3D printed implants market are helping reconstruction of entire facial features, limbs and tissue lost during serious illnesses such as Arthritis and much more.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=66527

Moreover, due to growing advancements in technologies such as nano-materials, today physicians can recreate exact replicas of individual anatomy and extend their services naturally. Moreover, critical surgeries like heart replacement and total joint replacement have also become feasible, thanks to virtual planning and guidance provided by 3D printed technology.

Currently new material advances such as polymer based hearts and other organs are making their ways into the medical field. Orthopedic implants like the ones made up of metals are also on the rise. This new material promotes osseointegration and increase the ability of surface bearing load capabilities. Today, many healthcare institutions, especially hospitals are introducing 3D printed machinery in their operations through radiology departments.

Additionally, the devices created using 3D printed technology are superior to conventional ones. For example, printed casts for fractured bones can be open and custom-fitted. These enable wearers to scratch, ventilate, and wash the damaged area. Additionally, these can also be recycled.

Request for Analysis of COVID-19 Impact on 3D Printed Implants Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=66527

The growing advancements in materials, supporting technology, and increasing medical applications are expected to drive significant growth for the printed implants market in the near future.

Global 3D Printed Implants Market: Notable Developments

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=66527

Global 3D Printed Implants Market: Key Trends

The global 3D printed implants market is witnessing positive developments such as identical bone customized implants, CT-bone, and zygoma augmentation process. The additional control over medical processes provided by the 3D printed implant technology is expected to create many opportunities for various players in the market. Moreover, rising R&D development, increase in medical surgeries, and growing biomedical applications of 3D technology are also expected to boost the 3D printed implants market.

Pre Book 3D Printed Implants Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=66527&ltype=S

However, high initial investments in the technology, lack of skilled technician, and longer production queues are expected to limit growth of the 3D printed implants market. However, the growth in cranial as well as orthopedic implants are likely to offset the setbacks in favor of the 3D printed implants market. The growth in the orthopedic segment reached an all-time high in 2018. It is expected to drive more tumor surgeries to create robust new opportunities.

Browse More Trending Reports by Transparency Market Research:

Internal Fixators Devices Market: https://www.transparencymarketresearch.com/internal-fixators-devices-market.html

Vena Cava Clips and Filters Market: https://www.transparencymarketresearch.com/vena-cava-clips-filters-market.html

Swine Flu Drugs Market: https://www.transparencymarketresearch.com/swine-flu-drugs-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Original post:
3D Printed Implants Market: Growing Biomedical Applications of 3D Technology is Expected to Boost the Market - BioSpace

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1.70 billion during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. The presence of large patient pool will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Neuropathy Pain Treatment Market 2020-2024: Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The neuropathy pain treatment market report covers the following areas:

This study identifies growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by drug class

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Visit link:
Neuropathy Pain Treatment Market Analysis Highlights the Impact of COVID-19 (2020-2024) |Presence of Large Patient Pool to boost the Market Growth |...

The pathophysiology of pain in neuropathy is complex and may be linked to sensory phenotypes. Quantitative sensory testing, a standardized method to evaluate sensory profiles in response to defined stimuli, assesses functional integrity of small and large nerve fiber afferents and central somatosensory pathways. It has revealed detailed insights into mechanisms of neuropathy, yet, it remains unclear if pain directly affects sensory profiles. The main objective of this study was to investigate sensory profiles in patients with various neuropathic conditions, including polyneuropathy, mononeuropathy, and lesions to the central nervous system, in relation to self-reported presence or absence of pain and pain sensitivity using the Pain Sensitivity Questionnaire.A total of 443 patients (332 painful and 111 painless) and 112 healthy participants were investigated. Overall, loss of sensation was equally prevalent in patients with and without spontaneous pain. Pain thresholds were equally lowered in both patient groups, demonstrating that hyperalgesia and allodynia is just as present in patients not reporting any pain. Remarkably, this was similar for dynamic mechanical allodynia. Hypoalgesia was more pronounced in painful polyneuropathy whereas hyperalgesia was more frequent in painful mononeuropathy (compared to painless conditions). Self-reported pain sensitivity was significantly higher in painful than in painless neuropathic conditions.Our results reveal the presence of hyperalgesia and allodynia in patients with central and peripheral lesions of the somatosensory system not reporting spontaneous pain. This shows that symptoms and signs of hypersensitivity may not necessarily coincide, and that painful and painless neuropathic conditions may mechanistically blend into one another.

PubMed

View post:
No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter...

More than half of women who underwent treatment for breast cancer experienced physical/functional complications involving an upper limb, according to results of a cross-sectional study published in Supportive Care in Cancer.1

Although a high incidence of posttreatment upper limb dysfunction has been previously reported in survivors of breast cancer, the aim of this study was to take a closer look at the underlying causes of this condition in women with a history of breast cancer.

Knowing what actually influences the development of upper limb dysfunction after breast cancer treatment can help healthcare professionals minimize the incidence of this complication, thus reducing the physical and functional impact of the disease and providing a better quality of life of survivors, the study authors commented.

This study involved adult women who had received breast cancer treatment between 2009 and 2016 at 1 of 2 institutions in Brazil.

Data related to sociodemographic characteristics and treatment history were collected during a patient interview and/or review of the patient medical record. The Disabilities of Arm, Shoulder and Hand (DASH) questionnaire was used to assess the impact of breast cancer treatment on the upper limb.2

Regarding the selection of the DASH questionnaire, the study authors explained that most of the instruments used to assess complications include physical examination with measurement of range of motion, muscle strength, and sensory capacity, and because they are limited to physical issues, many are unable to identify the level of independence and functionality for performing daily life activities related to the upper limbs.

They further clarified that the incorporation of patient-reported outcome measures into the DASH questionnaire also allowed for assessment of patient quality of life.

Other patient assessments included evaluations for the presence of lymphedema in the upper limb, breast skin sensitivity, paresthesia, pain, and scar adherence.

Of the 233 women included in this study, the mean patient age was 56.3 years. All patients underwent surgery for breast cancer with an average of approximately 5 years between surgical treatment and assessment. Lymphadenectomy was performed in 60.2% of patients, with the remaining patients having undergone either sentinel lymph node dissection or no surgical assessment of the lymph nodes. Approximately three-quarters of patients had received chemotherapy, radiation therapy, and were overweight/obese based on body mass index (BMI).

Key study findings included some level of upper limb dysfunction and evidence for sensory intercostobrachial nerve damage in 55.4% and 47.2% of patients, respectively.

Of note, analyses based on models adjusted for age and BMI showed that only paresthesia due to intercostobrachial nerve damage was significantly associated with upper limb dysfunction in these patients (odds ratio [OR], 1.96; 95% CI, 1.06-3.60; P =.03).

In summarizing the findings from this study, the study authors stated that upper limb dysfunction is a frequent complication after breast cancer treatment and may be associated with neuropathies due to changes in the intercostobrachial nerve pathway.

Reference

1. Siqueria TC, Fragoas SP, Pelegrini A, de Oliveira AR, Medeiros da Luz C. Factors associated with upper limb dysfunction in breast cancer survivors. Support Care Cancer. Published online August 17, 2020. doi:10.1007/s00520-020-05668-7

2. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther. 2001;14(2):128-146.

Visit link:
Neuropathy May Be Primary Cause of Upper Limb Dysfunction in Breast Cancer Survivors, Study Finds - Oncology Nurse Advisor

Diabetic neuropathy refers to the nerve damage caused due to diabetes. Diabetic neuropathy most often damages nerves in the legs and feet. However, it can injure nerve fibers throughout the body. Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes. Increasing diabetic population and growing awareness among people about diabetes and related complications are some of the major factors that drive the diabetic neuropathy market. Types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and other diabetic nerve damage. The peripheral diabetic neuropathy affects the feet and legs. It causes loss of sensation, and sometimes pain in the feet, legs, and hands. Autonomic diabetic neuropathy affects body functions such as heart rate, blood pressure, perspiration, and digestion. Proximal diabetic neuropathy affects thighs, hips, buttocks, and legs. Focal diabetic neuropathy affects the nerves, most often in the wrist, thigh, or foot. In addition, it also affects the nerves of the back, chest, and the nerves that control the eye muscles. Some of the factors that cause nerve damage in diabetes condition includes poor blood sugar control, kidney disease, smoking, excess weight, and length of time to have diabetes. However, anyone who has diabetes can develop neuropathy. Some symptoms of diabetic neuropathy are pain, tingling, numbness, and loss of feeling in the hands, arms, feet, and legs. The treatment options for diabetic neuropathy include drugs, radiotherapy, and physiotherapy.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/4795

The global diabetic neuropathy market is categorized based on medication, radiotherapy, and physiotherapy. Based on medication, the report covers antispasmodic, antidepressant, and others. Based on radiotherapy, the market comprises transcutaneous electrical nerve stimulation (TENS).

North America has the largest market for diabetic neuropathy, followed by Europe. This is due to the increasing number of patients with diabetes, rise in research and development activities, increasing awareness among people about diabetes and related complications, and improved healthcare infrastructure in the region. The diabetic neuropathy market in Asia is expected to experience high growth rate in the next few years. This is due to rising R&D activities for drug discovery and development, increasing government supports in the form of funding, growing awareness about diabetic neuropathy, and developing healthcare infrastructure in the region. In addition, growing demographics and economies in the developing countries such as India, China, and Japan are expected to lead growth in the diabetic neuropathy market in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/4795

Increasing prevalence of diabetes cases, growing, aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes and related nerve complications, and rise in R&D activities in drug discovery and developmemt are the key factors driving the global diabetic neuropathy market. However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs are some of the factors restraining the growth for global diabetic neuropathy market.

Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed in the global diabetic neuropathy market.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/4795

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
Demand for Diabetic Neuropathy Market to Witness Rapid Surge During the Period 2015 2021 - thedailychronicle.in

The research report on Peripheral Neuropathy Treatment market Size provides a thorough assessment of this business vertical. As per the study, the market is predicted to accumulate significant revenues and showcase a substantial growth rate during the estimated timeframe.

The Peripheral Neuropathy Treatment market report is a thorough investigation of the industry in terms of consumption and production. The report, based on the production facet, encompasses details regarding the manufacturing structure and profit margins of the renowned manufacturers. The price incurred by the companies to produce, store, and sell one unit of a product across the various geographies over the analysis period are also included in the study.

Speaking of the consumption aspect, the study details the consumption value and consumption volume of the products in question. Data pertaining to the individual sales price along with the import and export patterns spanning various territories are delivered in the report. Additionally, the report also predicts the production and consumption patterns over the assessment period.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/185890

Key pointers from the competitive landscape:

An outline of the regional landscape:

A brief overview of the product spectrum:

A summary of the application terrain:

In conclusion, the report evaluates the Peripheral Neuropathy Treatment market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are duly presented in the report.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/185890

Continued here:
Peripheral Neuropathy Treatment Market Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand and Forecast till 2025 - Express Journal

In 2029, the Neuropathy Pain Treatment market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Neuropathy Pain Treatment market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Neuropathy Pain Treatment market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Neuropathy Pain Treatment market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2641417&source=atm

Global Neuropathy Pain Treatment market report on the basis of market players

The report examines each Neuropathy Pain Treatment market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Neuropathy Pain Treatment market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Neuropathy Pain Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuropathy Pain Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuropathy Pain Treatment market.The following players are covered in this report:PfizerDepomedEli LillyEndoGrnenthal GroupArbor PharmaceuticalsNeuropathy Pain Treatment Breakdown Data by TypeCalcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthersNeuropathy Pain Treatment Breakdown Data by ApplicationRetail PharmaciesHospitalsOthers

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2641417&source=atm

The Neuropathy Pain Treatment market report answers the following queries:

The Neuropathy Pain Treatment market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2641417&licType=S&source=atm

Research Methodology of Neuropathy Pain Treatment Market Report

The global Neuropathy Pain Treatment market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Neuropathy Pain Treatment market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Neuropathy Pain Treatment market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read the original here:
Neuropathy Pain Treatment Market 10-Year Market Forecast and Trends Analysis Research Report - Scientect

The latest report on 2020-2029 Report on Global Neuropathy Pain Treatment Market by Player, Region, Type, Application and Sales Channel gives a broad assessment of the global Neuropathy Pain Treatment market by categorizing it in terms applications, types, and regions. The report gives a detailed analysis on competitive landscape and strategies that influenced the market in a positive way. Further, the report gives an overview of current market dynamics by studying various key segments based on the product, types, applications, end-to-end industries and market scenario.

Major Key Playersof Neuropathy Pain Treatment Market Report:Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Request a sample of this report @ https://www.regalintelligence.com/request-sample/159875

Market split by Type, can be divided into:

Calcium Channel Alpha 2-Delta Ligands

Serotonin-Norepinephrine Reuptake Inhibitors

Others

Market split by Application, can be divided into:

Retail Pharmacies

Hospitals

Others

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Market segment by Region/Country including:

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

Reach us to quote the effective price of this report @https://www.regalintelligence.com/check-discount/159875

Table of Contents

Chapter 1 Neuropathy Pain Treatment Market Overview

1.1 Neuropathy Pain Treatment Definition

1.2 Global Neuropathy Pain Treatment Market Size Status and Outlook (2014-2029)

1.3 Global Neuropathy Pain Treatment Market Size Comparison by Region (2014-2029)

1.4 Global Neuropathy Pain Treatment Market Size Comparison by Type (2014-2029)

1.5 Global Neuropathy Pain Treatment Market Size Comparison by Application (2014-2029)

1.6 Global Neuropathy Pain Treatment Market Size Comparison by Sales Channel (2014-2029)

1.7 Neuropathy Pain Treatment Market Dynamics (COVID-19 Impacts)

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Mergers/Acquisitions/Expansion)

1.7.4 COVID-19 Impacts on Current Market

1.7.5 Post-Strategies of COVID-19 Outbreak

Chapter 2 Neuropathy Pain Treatment Market Segment Analysis by Player

2.1 Global Neuropathy Pain Treatment Sales and Market Share by Player (2017-2019)

2.2 Global Neuropathy Pain Treatment Revenue and Market Share by Player (2017-2019)

2.3 Global Neuropathy Pain Treatment Average Price by Player (2017-2019)

2.4 Players Competition Situation & Trends

2.5 Conclusion of Segment by Player

Chapter 3 Neuropathy Pain Treatment Market Segment Analysis by Type

3.1 Global Neuropathy Pain Treatment Market by Type

3.1.1 Calcium Channel Alpha 2-Delta Ligands

3.1.2 Serotonin-Norepinephrine Reuptake Inhibitors

3.1.3 Others

3.2 Global Neuropathy Pain Treatment Sales and Market Share by Type (2014-2019)

3.3 Global Neuropathy Pain Treatment Revenue and Market Share by Type (2014-2019)

3.4 Global Neuropathy Pain Treatment Average Price by Type (2014-2019)

3.5 Leading Players of Neuropathy Pain Treatment by Type in 2019

3.6 Conclusion of Segment by Type

Chapter 4 Neuropathy Pain Treatment Market Segment Analysis by Application

4.1 Global Neuropathy Pain Treatment Market by Application

4.1.1 Retail Pharmacies

4.1.2 Hospitals

4.1.3 Others

4.2 Global Neuropathy Pain Treatment Sales and Market Share by Application (2014-2019)

4.3 Leading Consumers of Neuropathy Pain Treatment by Application in 2019

4.4 Conclusion of Segment by Application

Chapter 5 Neuropathy Pain Treatment Market Segment Analysis by Sales Channel

5.1 Global Neuropathy Pain Treatment Market by Sales Channel

5.1.1 Direct Channel

5.1.2 Distribution Channel

5.2 Global Neuropathy Pain Treatment Sales and Market Share by Sales Channel (2014-2019)

5.3 Leading Distributors/Dealers of Neuropathy Pain Treatment by Sales Channel in 2019

5.4 Conclusion of Segment by Sales Channel

Chapter 6 Neuropathy Pain Treatment Market Segment Analysis by Region

6.1 Global Neuropathy Pain Treatment Market Size and CAGR by Region (2014-2029)

6.2 Global Neuropathy Pain Treatment Sales and Market Share by Region (2014-2019)

6.3 Global Neuropathy Pain Treatment Revenue and Market Share by Region (2014-2019)

6.4 North America

6.4.1 North America Market by Country

6.4.2 North America Neuropathy Pain Treatment Market Share by Type

6.4.3 North America Neuropathy Pain Treatment Market Share by Application

6.4.4 United States

6.4.5 Canada

6.4.6 Mexico

6.5 Europe

6.5.1 Europe Market by Country

6.5.2 Europe Neuropathy Pain Treatment Market Share by Type

6.5.3 Europe Neuropathy Pain Treatment Market Share by Application

6.5.4 Germany

6.5.5 UK

6.5.6 France

6.5.7 Italy

6.5.8 Russia

6.5.9 Spain

6.6 Asia-Pacific

6.6.1 Asia-Pacific Market by Country

6.6.2 Asia-Pacific Neuropathy Pain Treatment Market Share by Type

6.6.3 Asia-Pacific Neuropathy Pain Treatment Market Share by Application

6.6.4 China

6.6.5 Japan

6.6.6 Korea

6.6.7 India

6.6.8 Southeast Asia

6.6.9 Australia

6.7 South America

6.7.1 South America Market by Country

6.7.2 South America Neuropathy Pain Treatment Market Share by Type

Excerpt from:
Post-pandemic Analysis on Neuropathy Pain Treatment Market Likely to Emerge Over A Period Of 2020 2029 - Galus Australis

A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.

Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia led the research. She and her colleagues tested the effect of venom on clinical subtypes of breast cancer, using the venom from 312 honeybees and bumblebees from Perth Western Australia, Ireland and England.

No one had previously compared the effects of honeybee venom or melittin across all of the different subtypes of breast cancer and normal cells, Dr. Duffy said. We tested honeybee venom on normal breast cells, and cells from the clinical subtypes of breast cancer: hormone receptor positive, HER2-enriched, and triple-negative breast cancer.

Dr. Duffy explained that the goal of the research was ultimately to determine if honeybee venom and its component compound, melittin, had anti-cancer properties.

We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells, said Dr. Duffy. The venom was extremely potent.

Melittin, in particular, also had a surprising effect. Within 20 minutes, the compound was able to reduce the chemical messages of cancer cells that are necessary for growth and cell division.

We looked at how honeybee venom and melittin affect the cancer signaling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signaling pathways were shut down, said Dr. Duffy. Melittin modulated the signaling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer.

Western Australias Chief Scientist Professor Peter Klinken noted that this study significantly demonstrates the potential benefits of melittin, and overall, how compounds in nature can be utilized to combat human diseases.

The researchers note that studies will be necessary to formally assess the best way to deliver melittin to patients.

This is not the only positive news that has come out of the breast cancer treatment realm as of late. Athenex also announced on Sept. 1 that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application for oral paclitaxel and encequidar for the treatment of metastatic breast cancer, and it has been granted Priority Review.

We see oral paclitaxel as a potentially important alternative to IV infusions, especially during the current pandemic, as it may allow cancer patients to take the oral chemotherapy at home, said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex. We believe the oral paclitaxel program validates our broader Orascovery platform, and we are committed to applying the technology to convert other IV chemotherapies into oral agents.

The NDA is based on data from a Phase 3 study of oral paclitaxel for the treatment of metastatic breast cancer. The trial was randomized and controlled, and looked at the safety and efficacy of oral paclitaxel monotherapy against IV paclitaxel monotherapy. It achieved its primary endpoint, demonstrating a statistically significant improvement in overall response rate, along with a lower neuropathy, compared to IV paclitaxel.

The FDA grants Priority Review to NDAs for potential drugs that, if approved, would make significant improvements to the way patients are treated for serious conditions, such as various types of cancer.

See the article here:
Could Bee Venom Be the Key to Treating Triple-Negative Breast Cancer? - PharmaLive

Erin Bryant, a physical therapist with Fyzical Therapy, said the body and the brain have the ability to heal with time. In Thieles case, she said, muscle memory and her former level of fitness will aid her recovery.

The therapy practice currently is working with three patients who have had COVID-19, including Thiele. All three cases are different, and all will require different treatment.

Theres no cookie-cutter for this, she said.

Christine Thiele, of Omaha, does a physical therapy session focusing on balance at WW Gym Wellness Workout in Omaha on Wednesday, August 26, 2020. Thiele had COVID-19 in the spring and is still struggling with lingering effects having to do with memory, balance and neuropathy.

Meanwhile, support groups for patients who have had COVID-19 have formed on Facebook and other forums. A group called Body Politic, which includes COVID-19 survivors, also has been involved in research.

Thiele has written about her situation on Facebook. She said doctors believe the virus triggered an autoimmune disease that has affected her mobility.

In the beginning, I was really trying to educate people to take this seriously, she said. Now its like, Look what its done to me. You guys really have to take it seriously.

Steve Schrader, too, has had a long road back.

Now 65, the La Vista man started in mid-March to experience symptoms, which he attributed to allergies. Those symptoms morphed into chest congestion and what he thought was a sinus infection. Schrader, who has asthma, battled it for a couple of weeks, as he usually does with chest congestion, including using a nebulizer.

See original here:
Even after the infection is gone, symptoms linger for COVID-19 'long-haulers' - Omaha World-Herald

MOUNT LAUREL, New Jersey, Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

https://2020.myana.org

SOURCE American Neurological Association

Continue reading here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PR Newswire India

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Exosome therapeutic marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

Read the original here:
Exosome Therapeutic Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 - Galus...

New York, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Veterinary Medicine Market by Product, Route of Administration, Animal Type, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 20202027" - https://www.reportlinker.com/p05955108/?utm_source=GNW

The veterinary medicine market accounted for $22,973 million in 2019, and is expected to reach $29,698 million by 2027, registering a CAGR of 4.6% from 2020 to 2027. Veterinary medicine is defined as a drug or other preparations employed in the treatment of animals. Furthermore, other preparations such as vaccines and medicated feed additives are also used to treat various medical conditions in animals. In addition, these medicines include different type of products such as anti-infective drugs, which are used to prevent, kill, or slow the growth of bacteria, fungi and other infection causing organisms. These medicines also include anti-inflammatory drugs, which are routinely used for relief of pain and inflammation associated with osteoarthritis, and other medical conditions in livestock and companion animals. Furthermore, parasiticide is another type of veterinary drug, which are employed in prevention or elimination of external and internal parasites such as fleas, ticks, and worms. Other than drugs, vaccines are also used in treatment of various medical conditions in animals. Some types of veterinary vaccines include inactivated vaccines, attenuated vaccines, and recombinant vaccine. Similarly, medicated feed additives are also used to cure medical conditions in livestock and companion animals. In addition, these different types of drugs are administered to animals through different routes such as oral, parenteral and topical. Furthermore, these drugs are used in treatment of companion animals such as dogs, cats and horses and are also used in treatment of livestock animals such as pigs, dairy cattle, beef cattle, and poultry. The major factors that contribute toward the growth of the veterinary medicine market include rise in number of pet owners and surge in livestock population across the globe. Furthermore, factors such as surge in prevalence of various medical conditions in animals and rise in demand for livestock products also boost growth of the veterinary medicine market. In addition, rise in animal healthcare expenditure is another major factor that fuels growth of the market. However, lack of veterinary infrastructure facilities in underdeveloped nations and stringent regulations associated with medicate feed additives restrict growth of the veterinary medicine market. Conversely, increase in awareness toward animal health offers a lucrative opportunity for the veterinary medicine market. The global veterinary medicine market is segmented on the basis of product, route of administration, animal type, distribution channel, and region to provide a detailed assessment of the market. By product, the market is divided into drugs, vaccines, and medicated feed additives. The drugs segment is further divided into anti-infective, anti-inflammatory, and parasiticide. In addition, the vaccines segment is divided into inactivated vaccines, attenuated vaccines, and recombinant vaccines. Similarly, the medicated feed additives segment is divided into amino acids and antibiotics. By route of administration, the market is classified into oral route, parenteral route, and topical route. By animal type, it is divided into companion animals and livestock animals. By distribution channel, it is classified into veterinary hospitals, veterinary clinics, and pharmacies & drug stores. By region, the veterinary medicine market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). The major players in the veterinary medicine market are Zoetis, Inc., Merck & Co., Inc. (Intervet International B.V.), Elanco Animal Health, Dechra Pharmaceuticals PLC, Ceva Sant Animale, Virbac., Vetoquinol S.A., Boehringer Ingelheim International GmbH., ADM Animal Nutrition, and Evonik Industries AG.

KEY BENEFITS FOR STAKEHOLDERS This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments. The market size and estimations are based on a comprehensive analysis of key developments in the industry. A qualitative analysis based on innovative products facilitates strategic business planning. The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments By Product o Drugs - Anti-infective - Anti-inflammatory - Parasiticide o Vaccines - Inactivated Vaccines - Attenuated Vaccines - Recombinant Vaccines o Medicated Feed Additives - Amino Acids - Antibiotics By Route of Administration o Oral Route o Parenteral Route o Topical Route By Route of Administration o Oral Route o Parenteral Route o Topical Route By Animal Type o Companion Animals o Livestock Animals

By Distribution Channel o Veterinary Hospital Pharmacies o Retail Veterinary Pharmacies By Region o North America - U.S. - Canada - Mexico o Europe - Germany - France - UK - Italy - Spain - Rest of Europe o Asia-Pacific - Japan - China - India - Australia - South Korea - Rest of Asia-Pacific

o LAMEA - Brazil - Saudi Arabia - South Africa - Rest of LAMEA List of key players profiled in the report: Zoetis, Inc. Merck & Co., Inc. (Intervet International B.V.) Elanco Animal Health Dechra Pharmaceuticals PLC Ceva Sant Animale Virbac. Vetoquinol S.A. Boehringer Ingelheim International GmbH. ADM Animal Nutrition Evonik Industries AG

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request) Pharmgate Inc. Bimedia, Inc.Read the full report: https://www.reportlinker.com/p05955108/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
The veterinary medicine market accounted for $22,973 million in 2019, and is expected to reach $29,698 million by 2027, registering a CAGR of 4.6%...

Dr. Anthony S. Johnson, DVM, DACVECC, a leading veterinary professional and current Medical Director of the Veterinary Information Network (VIN), has been spotlighted in a new exclusive interview with Inspirery.

PLAINFIELD, IL / ACCESSWIRE / September 3, 2020 / The interview, which was published on August 27, 2020, can be found here on the official site. Inspirery features exclusive and in-depth interviews with accomplished entrepreneurs and executives from around the world.

The interview covered a broad range of business-related topics, including how Dr. Anthony S. Johnson launched his highly successful career in the veterinary profession, how he currently generates revenue, how he acquired his very first customer, and what marketing and new customer acquisition strategies are generating the most impact and return on investment.

In addition, Dr. Anthony S. Johnson provided insights on what he attributes his success to, what he believes the future holds for his business, what the toughest decision he's made in the last few months was, what advice he would give his younger self, and whether he would be willing to be a mentor to those aspiring to enter or establish themselves in the veterinary emergency and critical care field. Not surprising to anyone who knows him and his generous nature, he responded to this request with an emphatic yes.

Dr. Anthony S. Johnson also listed four business books that have inspired him over the years: Blue Ocean Strategy by Rene Mauborgne and W. Chan Kim, How Doctors Think by Jerome Groopman, The Checklist Manifesto by Atul Gawande, and Thinking, Fast and Slow by Daniel Kahneman. He also shared his enthusiasm about entering his 13th year of teaching an acclaimed and popular online class for new graduate veterinarians, which focuses on the basics of emergency room medicine.

"I have always enjoyed teaching, and am proud of the online course and the thousands of veterinarians that we have helped educate over the years," commented Dr. Anthony S. Johnson, who between 2009 and 2014 served as a Clinical Assistant Professor at Purdue University's College of Veterinary Medicine, where he taught a wide range of undergraduate, graduate and professional-level courses. "I believe that I have a duty and responsibility to give back to the profession by sharing my knowledge and experiences. The field of veterinary medicine is dynamic, and there are many exciting developments on the horizon driven by technologies like artificial intelligence and machine learning."

About Dr. Anthony S. Johnson

Dr. Anthony S. Johnson DVM, DACVECC, is a leading veterinary professional and educator who has filled a myriad of executive-level roles in veterinary centers across the U.S., including Critical Care Specialist, Emergency Department Head, and Co-Head. Currently, he is the Medical Director of the Veterinary Information Network (VIN). Dr. Johnson and his family recently relocated to the Chicago area from Carmel, Indiana. Known for his big smile, open heart, and wonderful sense of humor, when he is not working or spending time with his wife and their three children, Dr. Anthony S. Johnson enjoys occasional forays into woodworking, cooking, wine, reading, and writing. For more information about Anthony S. Johnson, please visit: https://anthonysjohnson.net/

Contact Information:

Anthony S. JohnsonEmail: Tony@VIN.comPhone: 503-522-3837

SOURCE: Dr. Anthony S. Johnson

View source version on accesswire.com: https://www.accesswire.com/604710/Leading-Veterinary-Professional-Dr-Anthony-S-Johnson-Spotlighted-in-New-Exclusive-Interview-with-Inspirery

View original post here:
Leading Veterinary Professional Dr. Anthony S. Johnson Spotlighted in New Exclusive Interview with Inspirery - Yahoo Finance

The state-of-the-art center steps up to aid the region's adoption network.

When longtime philanthropistsTina and George Skestos, founder of Homewood Corp., started working on a legacy project, they decided to address the troubles of a dog-rescue network burdened with overcrowding and costly medical care. After talking with dean Rustin Moore of the Ohio State University College of Veterinary Medicine, Columbus Humane CEO Rachel Finney and several veterinarians, the Skestoses noticed a problem of supply and demand. In Southern Ohio, rural shelters were overwhelmed by unwanted dogs and their medical care, yet Central Ohios counterparts could not keep up with the demand for adoptions.

It was being solved by putting dogs in a van and taking them from point A to point B, then causing more costs to the system as dogs transferred with health conditions, says Justin McKinniss, acting CEO of Gigis Shelter for Dogs, the Skestoses expansive center. George thought if you put a dollar in the middle of the system, it would save two dollars on each side.

Opened in 2018, the $4 million, 26,000-square-foot complex and its 19-member staff examine and treat up to 1,500 dogs annually. The dogs arrive from six partner shelters and typically spend three days at Gigis before being transferred to one of 17 adoption centers. On day one, they receive medical care. Day two, they are evaluated for their behavior, and on day three, they are spayed and neutered. During their stay, theyre kenneled in four separate wards to minimize the spread of disease. Dogs receive care at the state-of-the-art medical center featuring two surgical suites, two veterinarians, a dental suite, exam rooms, X-ray equipment and an isolated parvovirus treatment clinic.

The newest addition is a behavioral center directed by Meghan Herron, one of only three behavioral vets nationally within the shelter community. Dogs receive training to overcome behavioral issues and prepare them for adoption. The shelter now serves as a nationwide model, earning a spot among this years Petco Unsung Hero award finalists, alongside Gigis Shelter board president Jim Phieffer.

Beyond its own operation, Gigis invests in its partners facilities and equips them with vaccines, medical equipment and training. Gigis is the first of its kind, says Finney, who has worked with Gigis from the start. There were lots of transfer agencies, but this was the first that invested in the source shelters. Its not good enough to remove a dog from a [difficult] situation; its about helping agencies do a better job for all dogs.

Before Gigis, we would import litters of puppies with no medical or behavioral information and find out they had parvovirus once they arrive, says Kelsey Smucker, director of CHA Animal Shelter in Westerville. She explains that they would have to pay thousands of dollars to treat this highly infectious and deadly disease thats especially threatening to puppies. Now, Gigis has the facilitiesto quarantine and treat parvovirus as well as intervene with many other medical conditions.

When Gigis dogs arrive at our shelter, they go right on our adoption floor and often are adopted the first day, says Smucker.

While the shelter has garnered recognition, Tina Skestos says the biggest reward is seeing its adoptees, including several she and her husband pass on neighborhood walks with their Akita, Gigi, the shelters namesake. Its great to see the happy faces on these dogs and the joy they bring to these families, Tina says. All these dogs deserve a chance.

Originally posted here:
Gigis Shelter for Dogs is Coming to the Rescues - Columbus Monthly